期刊文献+

GM_1对帕金森病治疗作用的实验研究 被引量:3

An Experimental Study on the Treatment of Pakinson's Disease with GM_1
暂未订购
导出
摘要 研究单唾液酸四己糖神经节苷脂 (GM1 )对帕金森病 (PD)的治疗作用。运用选择性偏侧 (右侧 ) PD大鼠模型 ,观测正常对照组、 PD组 (造模后 14d)、 PD生理盐水 (NS)治疗组和 GM1 治疗组 (10 mg/ kg IP qd、连续 14d) ,阿朴吗啡 (APO)诱发的旋转行为改变和纹状体线粒体钙 (MCa)、钙调素 (Ca M)含量改变。PD组表现明显的 APO诱发的旋转行为 (≥ 6 r/ m in) ,黑质损伤侧 (右侧 )纹状体 MCa、Ca M含量与正常对照组比较显著性升高 (P<0 .0 1) ;GM1 治疗组 APO诱发的旋转行为明显好转 ,黑质损伤侧纹状体 MCa、 Ca M含量与 PD组比较无显著差异性 (P>0 .0 5 )。GM1 能改善实验性 PD的部分行为、生化改变 ,对 The treatment of Parkinson's disease (PD) with GM 1 was studied. By using selective lateral (right) rat PD model, the changes in rotational behavior induced by apomorphine (APO), striatum mitochondria calcium (MCa), Calmodulin (CaM) contents in the control group, PD group, normal sodium group (NS) and GM 1 treated PD group (10 mg/kg IP, once daily for 14 days) were observed. In PD group (14 days) obvious APO induced rotational behaviors (≥6 r/min) was observed. As compared with control group, striatum Mca and CaM contents on the injured side (right) of substantia nigra were increased significantly ( P <0.01). The APO induced rotational behaviors and striatum Mca and CaM contents in the GM 1 treated PD group were improved significantly ( P <0.01), but there was no significant difference in MCa and CaM contents in the injured side of substantia nigra between the NS treated PD group and PD groups ( P >0.05). GM 1 could partially improve the behavioral and biochemical changes of experimental PD and had therapeutic effects on PD.
出处 《同济医科大学学报》 CAS CSCD 2000年第5期414-416,共3页 Acta Universitatis Medicinae Tongji
关键词 GM1 帕金森病 线粒体钙 钙调素 实验研究 治疗 Parkinson's disease GM 1 mitochondria calcium Calmodulin
  • 相关文献

参考文献1

共引文献4

同被引文献22

  • 1邵震宇,刘忆林,姜伟.单唾液酸四己糖神经节苷酯治疗帕金森病1例[J].医药导报,2004,23(9):657-657. 被引量:5
  • 2许爱国,王天然,李丽萍,白小红,张丽华,蒋燕,马布仁.呼吸疾病患者血清神经节苷脂含量及其意义[J].西南军医,2005,7(1):10-12. 被引量:4
  • 3李振光.从自由基学说探讨帕金森病的病因与治疗进展[J].国外医学(老年医学分册),1994,15(1):1-4. 被引量:4
  • 4尹琳琳,朱兴族.帕金森病的发病机制及其药物治疗研究进展[J].国外医学(药学分册),2006,33(2):93-96. 被引量:13
  • 5王新德.帕金森病及帕金森综合征的诊断标准和鉴别诊断[J].中华神经精神科杂志,1985,18(4):256-256.
  • 6Kenneth O,Lloyd.Cell surface accessibility of individual gangliosides in malignant melanoma cells to antibodies is influenced by the total ganglioside composition of the cells[J].Cancer Res,1992,52(18):4948-4953.
  • 7L Svennerholm.Gangliosides--a new therapeutic agent against stroke and Alzheimer's disease[J].Life Sci,1994,55(25-26):2125-2134.
  • 8Hee-Jung Choi,Tae-Wook Chung,et al.Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression-transcriptional induction of p21WAF1 and p27kip1 by inhibition of PI-3K/AKT pathway[J].Glycobiology,2006,16(7):573-583.
  • 9Tae-Wook Chung,Seok-Jo Kim,et al.Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis:Direct interaction of GM3 with VEGFR-2[J].Glycobiology,2009,19(3):229-239.
  • 10Heegaard NH,Hansen SI,Holm J.A novel specific heparin-binding activity of bovine folate-binding p rotein characterized by capillary electrophoresis[J].Electrophoresis,2006,27(5-6):1112-1117.

引证文献3

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部